|
시장보고서
상품코드
1998716
전립선 특이항원 검사 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)Prostate-Specific Antigen Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035 |
||||||
세계의 전립선 특이항원 검사 시장은 2025년에 51억 달러로 평가되었고, CAGR7.1%로 성장하여 2035년까지 101억 달러에 달할 것으로 예측됩니다.
전립선암의 유병률 증가, PSA 검사의 지속적인 기술 발전, 세계 진단 검사 시설 인프라의 발전으로 인해 시장 확대가 이루어지고 있습니다. PSA 검사는 전립선에서 생성되는 단백질 수치를 측정하는 검사로 전립선암의 조기 발견, 질병 진행 상황 모니터링, 치료 결과 평가에 도움이 됩니다. 고감도 분석, 자동 면역 측정 시스템, 검사 정확도 향상 등의 기술 혁신으로 PSA 검사에 대한 임상적 신뢰도가 높아지고 있습니다. PSA 밀도, PSA 속도, 반사 검사와 같은 추가 기법은 진단의 정확도를 높이고 임상 현장에서 더 광범위하게 채택될 수 있도록 지원합니다. 업계는 PSA 검사를 고급 진단 워크플로우에 통합하여 조기 발견과 과잉 진단을 최소화하는 균형을 맞추기 위해 위험 기반 스크리닝 전략으로 전환하고 있습니다. 연령, 인종, 가족력, 기저 PSA 수치, 동반 질환 등의 요인이 검사 결정에 영향을 미치는 경우가 많아지면서 PSA 검사는 보다 타겟이 명확하고 치료적 연관성이 높아졌습니다.
예비 검사 부문은 초기 스크리닝 도구로 널리 사용되고 있어 2025년 68%의 점유율을 차지했습니다. 총 PSA, 유리 PSA 비율 및 1차 선별검사 패널은 일반적으로 침습적 치료를 권장하기 전에 암 위험을 평가하기 위해 사용됩니다. 이러한 검사는 비용 효율적이고 접근성이 높으며 비침습적이기 때문에 임상의가 환자를 계층화하고 불필요한 생검을 피함으로써 보다 안전한 임상적 판단을 내릴 수 있도록 돕습니다.
| 시장 범위 | |
|---|---|
| 개시 연도 | 2025년 |
| 예측 연도 | 2026-2035년 |
| 개시 금액 | 51억 달러 |
| 예측 금액 | 101억 달러 |
| CAGR | 7.1% |
전립선암 검진 부문은 2025년 53.5%의 점유율을 차지했으며, 2035년까지 51억 달러에 달할 것으로 전망됩니다. PSA 검사는 특히 고령화 사회에서 조기 발견에 매우 중요한 역할을 하고 있으며, 대상별 검진 프로그램과 집단 검진 프로그램 모두에서 도입을 촉진하고 있습니다. 체계적인 검진 이니셔티브에 대한 정부 및 기관의 지원은 재정적, 물류적 장벽을 낮추고 검진율을 더욱 높이고 있습니다.
북미 전립선 특이항원 검사 시장은 전립선암의 높은 발병률, 남성 인구의 고령화, 조기 발견에 대한 높은 인식에 힘입어 2025년 36.9%의 점유율을 차지헀습니다. 병원, 전문 클리닉 및 진단 검사 기관에서는 PSA 검사가 표준 검진 프로그램에 일상적으로 통합되어 있습니다. 최첨단 검사실과 현장 진료 시설을 포함한 첨단 의료 인프라와 더불어 차세대 검사법에 대한 막대한 투자가 이 지역에서 PSA 검사의 급속한 보급과 폭넓은 활용을 촉진하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법
제2장 주요 요약
제3장 업계 인사이트
제4장 경쟁 구도
제5장 시장 추산 및 예측 : 제품별, 2022년-2035년
제6장 시장 추산 및 예측 : 용도별, 2022년-2035년
제7장 시장 추산 및 예측 : 최종 용도별, 2022년-2035년
제8장 시장 추산 및 예측 : 지역별, 2022년-2035년
제9장 기업 개요
LSH 26.04.23The Global Prostate-Specific Antigen Test Market was valued at USD 5.1 billion in 2025 and is estimated to grow at a CAGR of 7.1% to reach USD 10.1 billion by 2035.
The market's expansion is fueled by the increasing prevalence of prostate cancer, ongoing technological advancements in PSA testing, and the growth of diagnostic laboratory infrastructure worldwide. PSA tests measure the level of a protein produced by the prostate gland, aiding in the early detection of prostate cancer, monitoring disease progression, and assessing treatment outcomes. Technological innovations, such as high-sensitivity assays, automated immunoassay systems, and improved test accuracy, have strengthened clinical confidence in PSA testing. Additional methods, including PSA density, PSA velocity, and reflex testing, enhance diagnostic precision, supporting broader clinical adoption. The industry is moving toward risk-based screening strategies, integrating PSA testing with advanced diagnostic workflows to balance early detection with minimizing overdiagnosis. Factors such as age, ethnicity, family history, baseline PSA levels, and comorbidities increasingly guide testing decisions, making PSA testing more targeted and therapeutically relevant.
The preliminary tests segment held 68% share in 2025 owing to its widespread use as an initial screening tool. Total PSA, free PSA ratio, and first-line screening panels are commonly employed to evaluate cancer risk before recommending invasive procedures. These tests are cost-effective, accessible, and non-invasive, helping clinicians stratify patients and avoid unnecessary biopsies, thereby supporting safer clinical decisions.
| Market Scope | |
|---|---|
| Start Year | 2025 |
| Forecast Year | 2026-2035 |
| Start Value | $5.1 Billion |
| Forecast Value | $10.1 Billion |
| CAGR | 7.1% |
The prostate cancer screening segment held a 53.5% share in 2025 and is projected to reach USD 5.1 billion through 2035. PSA testing continues to play a crucial role in early detection, particularly in aging populations, driving its adoption in both targeted and population-based screening programs. Government and institutional support in organized screening initiatives reduces financial and logistical barriers, further increasing test uptake.
North America Prostate-Specific Antigen Test Market accounted for 36.9% share in 2025, driven by the high incidence of prostate cancer, an aging male population, and strong awareness of early detection. Hospitals, specialty clinics, and diagnostic laboratories routinely incorporate PSA testing into standard screening programs. Advanced healthcare infrastructure, including state-of-the-art laboratories and point-of-care facilities, along with high investment in next-generation assays, facilitates rapid adoption and widespread availability of PSA tests in the region.
Key players in the Global Prostate-Specific Antigen Test Market include Abbott, AdvaCare Pharma, Beckman Coulter, BIOMERIEUX, CTK Biotech, DiaSorin, Fujirebio, Intec, KOELIS, Labcorp, mdxhealth, Myriad Genetics, OPKO Health, Roche, and SIEMENS Healthineers. Companies in the Global Prostate-Specific Antigen Test Market are employing multiple strategies to strengthen their market foothold. They focus on product innovation, developing highly sensitive, automated, and user-friendly assays for accurate early detection and monitoring. Strategic partnerships with hospitals, diagnostic labs, and healthcare networks expand distribution and adoption. Investment in R&D ensures next-generation technologies, improved assay performance, and regulatory compliance. Geographic expansion into high-growth regions increases market penetration, while marketing campaigns emphasize accuracy, reliability, and clinical relevance. Firms also provide training and technical support to laboratories and clinicians to enhance usage and build long-term customer loyalty, thereby solidifying their competitive positioning.
Table of Contents
Chapter 1 Research Methodology
- 1.1 Research approach
- 1.2 Quality commitments
- 1.2.1 GMI AI policy & data integrity commitment
- 1.2.1.1 Source consistency protocol
- 1.2.1 GMI AI policy & data integrity commitment
- 1.3 Research trail & confidence scoring
- 1.3.1 Research trail components
- 1.3.2 Scoring components
- 1.4 Data collection
- 1.4.1 Partial list of primary sources
- 1.5 Data mining sources
- 1.5.1 Paid sources
- 1.5.1.1 Sources, by region
- 1.5.1 Paid sources
- 1.6 Base estimates and calculations
- 1.6.1 Base year calculation for any one approach
- 1.7 Forecast model
- 1.7.1 Quantified market impact analysis
- 1.7.1.1 Mathematical impact of growth parameters on forecast
- 1.7.1 Quantified market impact analysis
- 1.8 Research transparency addendum
- 1.8.1 Source attribution framework
- 1.8.2 Quality assurance metrics
- 1.8.3 Our commitment to trust
Chapter 2 Executive Summary
- 2.1 Industry 3600 synopsis
- 2.2 Key market trends
- 2.2.1 Regional trends
- 2.2.2 Product trends
- 2.2.3 Application trends
- 2.2.4 End use trends
- 2.3 CXO perspectives: Strategic imperatives
- 2.3.1 Key decision points for industry executives
- 2.3.2 Critical success factors for market players
- 2.4 Future outlook and strategic recommendations
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing incidence of prostate cancer
- 3.2.1.2 Adoption of personalized healthcare and preventive diagnostics
- 3.2.1.3 Technological advancements in diagnostic assays and point-of-care testing
- 3.2.1.4 Rising awareness of early detection and screening
- 3.2.2 Industry pitfalls and challenges
- 3.2.2.1 High cost of advanced PSA testing technologies
- 3.2.2.2 Limited specificity and false positives leading to overdiagnosis
- 3.2.3 Market opportunities
- 3.2.3.1 Development of next-generation and multi-marker diagnostic platforms
- 3.2.3.2 Growth in home-based and decentralized testing solutions
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.4.1 North America
- 3.4.2 Europe
- 3.4.3 Asia Pacific
- 3.5 Technology landscape
- 3.5.1 Current technological trends
- 3.5.2 Emerging technologies
- 3.6 Reimbursement scenario
- 3.7 Future market trends
- 3.8 Pricing analysis, 2025
- 3.9 Porter's analysis
- 3.10 PESTEL analysis
- 3.11 Customer insights
- 3.12 Start-up scenarios
- 3.13 Investment landscape
- 3.14 Gap analysis
Chapter 4 Competitive Landscape, 2025
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Company market share analysis
- 4.3.1 Global
- 4.3.2 North America
- 4.3.3 Europe
- 4.3.4 Asia Pacific
- 4.4 Competitive positioning matrix
- 4.5 Competitive analysis of major market players
- 4.6 Key developments
- 4.6.1 Mergers & acquisitions
- 4.6.2 Partnerships & collaborations
- 4.6.3 New product launches
- 4.6.4 Expansion plans
Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)
- 5.1 Key trends
- 5.2 Preliminary tests
- 5.2.1 Total prostate specific antigen test
- 5.2.2 Complex prostate specific antigen test
- 5.2.3 Free prostate specific antigen test
- 5.3 Confirmatory tests
- 5.3.1 Biopsy
- 5.3.2 Trans-rectal ultrasound
- 5.3.3 PCA3Test
Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)
- 6.1 Key trends
- 6.2 Prostate cancer screening
- 6.3 Prostate cancer monitoring
Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)
- 7.1 Key trends
- 7.2 Hospitals
- 7.3 Diagnostic centers
- 7.4 Specialty clinics
- 7.5 Other end users
Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)
- 8.1 Key trends
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Argentina
- 8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
Chapter 9 Company Profiles
- 9.1 Abbott
- 9.2 AdvaCare Pharma
- 9.3 Beckman Coulter
- 9.4 BIOMERIEUX
- 9.5 CTK Biotech
- 9.6 DiaSorin
- 9.7 Fujirebio
- 9.8 Intec
- 9.9 KOELIS
- 9.10 Labcorp
- 9.11 mdxhealth
- 9.12 Myriad Genetics
- 9.13 OPKO Health
- 9.14 Roche
- 9.15 SIEMENS Healthineers
